Y-mAbs Therapeutics, Inc. is a U.S.-based pharmaceutical company with a medium risk rating score of 27.6. Specializing in ESG friendly novel antibody-based therapeutic products for cancer treatment. DANYELZA, their FDA-approved product, targets ganglioside GD2 expressed in neuroectoderm-derived tumors and sarcomas.